Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702656 | 0.84 | OGT (0.45) | MMP1ITGB1ITGA4ALDH1A1MAPT | |
| SCHEMBL3702653 | 0.84 | OGT (0.45) | MMP1ITGB1ITGA4ALDH1A1MAPT | |
| SCHEMBL3698356 | 0.82 | MMP1 (0.66) | MMP1ITGB1ITGA4 | |
| SCHEMBL3698358 | 0.82 | MMP1 (0.66) | MMP1ITGB1ITGA4 | |
| SCHEMBL3701143 | 0.77 | MMP1 (0.48) | MMP1ITGB1ITGA4 | |
| SCHEMBL3701146 | 0.77 | MMP1 (0.48) | MMP1ITGB1ITGA4 | |
| SCHEMBL7543971 | 0.76 | MMP1 (0.54) | MMP1ITGB1ITGA4 | |
| SCHEMBL8739096 | 0.74 | ITGB1 (0.44) | MMP1ITGB1ITGA4 | |
| SCHEMBL7544562 | 0.74 | MMEL1 (0.55) | MMP1ITGB1ITGA4TACR2 | |
| SCHEMBL3706048 | 0.73 | MMP1 (0.70) | MMP1ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | PSMB1 2344/4885PSMB5 786/4885PSMB2 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.